Health tech startup Guardant Health has raised a fresh $30 million round of funding.

The startup is focused on developing a non-invasive cancer screening tool called Guardant 360 that uses blood samples instead of tissue, as VentureBeat previously reported. The screening tool was built to help patients avoid getting risky biopsies, which can cost around $10,000 for someone without health insurance.

Guardant said it plans to use the new capital to expand the commercial release of its cancer screening tool. The funding round was led by Khosla Ventures with participation from Sequoia Capital and Pejman Mar Ventures.

Founded in 2012, the Redwood City, Calif.-based startup has now raised a total of $40 million in funding to date.

Get more stories like this on TwitterFacebook

Guardant Health is transforming the art of medicine into science by developing a suite of tools that will empower physicians and patients in their quest for certainty in diagnosis and treatm... All Guardant Health news »

Track Guardant Health's Landscape to stay on top of the industry. Access the entire ecosystem, track innovation & deals. Learn more.